Your browser doesn't support javascript.
loading
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
Iiizumi, Susumu; Ohtake, Junya; Murakami, Naoko; Kouro, Taku; Kawahara, Mamoru; Isoda, Fumiko; Hamana, Hiroshi; Kishi, Hiroyuki; Nakamura, Norihiro; Sasada, Tetsuro.
Afiliação
  • Iiizumi S; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. iizumi_s@brightpathbio.com.
  • Ohtake J; Research & Early Development Division, BrightPath Biotherapeutics Co., Ltd., 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan. iizumi_s@brightpathbio.com.
  • Murakami N; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. qsl.suivx2000@gmail.com.
  • Kouro T; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. n.murakami_0131v2@outlook.jp.
  • Kawahara M; Research & Early Development Division, BrightPath Biotherapeutics Co., Ltd., 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan. n.murakami_0131v2@outlook.jp.
  • Isoda F; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. kourot@gancen.asahi.yokohama.jp.
  • Hamana H; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. mmrkawahara@gancen.asahi.yokohama.jp.
  • Kishi H; Department of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan. isoda_f@brightpathbio.com.
  • Nakamura N; Research & Early Development Division, BrightPath Biotherapeutics Co., Ltd., 3-25-22 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan. isoda_f@brightpathbio.com.
  • Sasada T; Department of Innovative Cancer Immunotherapy, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. hamana@med.u-toyama.ac.jp.
Cancers (Basel) ; 11(2)2019 Feb 24.
Article em En | MEDLINE | ID: mdl-30813491
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão